Dose-response trial of lactoferrin in patients with chronic hepatitis C

Japanese Journal of Cancer Research

Volumn 93, Issue 9, 2002, Pages 1063-1069

  Okada, Shuichi ^a   Tanaka, Katsuaki ^e   Sato, Tosiya ^f   Ueno, Hideki ^a   Saito, Satoru ^e   Okusaka, Takuji ^a   Sato, Keiko ^b   Yamamoto, Seiichiro ^c   Kakizoe, Tadao ^d  

^a National Cancer Center   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^f KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

Alanine aminotransaminase; Chronic hepatitis C; Hepatitis C virus; Lactoferrin

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; IRON BINDING PROTEIN; LACTOFERRIN; VIRUS RNA;

ADULT; AGED; ANOREXIA; ANTIVIRAL ACTIVITY; ARTICLE; BIOCHEMISTRY; CELL CULTURE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; MALE; PATHOGENESIS; PRIORITY JOURNAL; RASH; RELAPSE; RISK FACTOR; VIROLOGY; BLOOD; MIDDLE AGED;

ADULT; AGED; ALANINE TRANSAMINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LACTOFERRIN; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 0036747346     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb02484.x     Document Type: Article

References (32)

1. Di Bisceglie, A. M. Hepatitis C and hepatocellular carcinoma. Hepatology, 26 (Suppl. 1), 34S-38S (1997).
2. Takano, S., Yokosuka, O., Imazeki, F., Tagawa, M. and Omata, M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology, 21, 650-655 (1995).
3. Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschikamp, M., Hurter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W. and Haussingger, D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 28, 1687-1695 (1998).
4. Hoofnagle, J. H. and Di Bisceglie, A. M. The treatment of chronic viral hepatitis. N. Engl. J. Med., 336, 347-356 (1997).
5. Davis, G. L. Current therapy for chronic hepatitis C. Gastroenterology, 118, S104-S114 (2000).
6. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M. H., Cort, S. and Albrecht J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med., 339, 1485-1492 (1998).
7. Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M. H. and Albrecht, J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med., 339, 1493-1499 (1998).
8. Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C. and Albrecht, J. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 352, 1426-1432 (1998).
9. Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J. and Brunda, M. J. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med., 343, 1666-1672 (2000).
10. Heathcote, E. J., Shiffman, M. L., Cooksley, G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., Hoffman, J. and De Pamphilis, J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med., 343, 1673-1680 (2000).
11. Lonnerdal, B. and Iyer, S. Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr., 15, 93-110 (1995).
12. Levay, P. F. and Viljoen, M. Lactoferrin: a general review. Haematologica, 80, 252-267 (1995).
13. Hasegawa, K., Motsuchi, W., Tanaka, S. and Dosako, S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol., 47, 73-85 (1994).
14. Fujihara, T. and Hayashi, K. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch. Virol., 140, 1469-1472 (1995).
15. Defer, M. C., Dugas, B., Picard, O. and Damais, C. Impairment of circulating lactoferrin in HIV-1 infection. Cell. Mol. Biol., 41, 417-421 (1995).
16. Harmsen, M. C., Swart, P. J., de Bethune, M. P., Pauwels, R., De Clercq, E., The, T. H. and Meijer, D. K. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis., 172, 380-388 (1995).
17. Ikeda, M., Sugiyama, K., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K. and Kato, N. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Biophys. Res. Commun., 245, 549-553 (1998).
18. Ikeda, M., Nozaki, A., Sugiyama, K., Tanaka, T., Naganuma, A., Tanaka, K., Sekihara, H., Shimotohno, K., Saito, M. and Kato, N. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res., 66, 51-63 (2000).
19. Yi, M., Kaneko, S., Yu, D. Y. and Murakami, S. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol., 71, 5997-6002 (1997).
20. Tanaka, K., Ikeda, M., Nozaki, A., Kato, N., Tsuda, H., Saito, S. and Sekihara, H. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn. J. Cancer Res., 90, 367-371 (1999).
21. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J. Jpn. Soc. Cancer Ther., 28, 101-130 (1993).
22. Shibuya, M. Adverse drug reaction criteria of the Japan Society for Cancer Therapy. Jpn. J. Cancer Chemother., 24, 2036-2041 (1997).
23. Tsukiyama-Kohara, K., Kohara, M., Yamaguchi, K., Maki, N., Toyoshima, A., Miki, K., Tanaka, S., Hattori, N. and Nomoto, A. A second group of hepatitis C viruses. Virus Genes, 5, 243-254 (1991).
24. Tanaka, T., Tsukiyama-Kohara, K., Yamaguchi, K., Yagi, S., Tanaka, S., Hasegawa, A., Ohta, Y., Hattori, N. and Kohara, M. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology, 19, 1347-1353 (1994).
25. Simmonds, P., McOmish, F., Yap, P. L., Chan, S.-W., Lin, C. K., Dusheiko, G., Saeed, A. A. and Holmes, E. C. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J. Gen. Virol., 74, 661-668 (1993).
26. Bedossa, P., Poynard, T. and for The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology, 24, 289-293 (1996).
27. Armstrong, G. L., Alter, M. J., McQuillan, G. M. and Margolis, H. S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology, 31, 777-782 (2000).
28. Iyer, S. and Lonnerdal, B. Lactoferrin, lactoferrin receptors and iron metabolism. Eur. J. Clin. Nutr., 47, 232-241 (1993).
29. Sykes, J. A., Thomas, M. J., Goldie, D. J. and Turner, G. M. Plasma lactoferrin levels in pregnancy and cystic fibrosis. Clin. Chim. Acta, 122, 385-393 (1982).
30. Baynes, R., Bezwoda, W., Bothwell, T., Khan, Q. and Mansoor, N. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. Scand. J. Clin. Lab. Invest., 46, 695-704 (1986).
31. Hansen, N. E., Malmquist, J. and Thorell, J. Plasma myeloperoxidase and lactoferrin measured by radioimmunoassay: relations to neutrophil kinetics. Acta Med. Scand., 198, 437-443 (1975).
32. Olofsson, T., Olsson, I, Venge, P. and Elgefors, B. Serum myeloperoxidase and lactoferrin in neutropenia. Scand. J. Haematol., 18, 73-80 (1977).